Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis.

IF 3.1 3区医学 Q2 HEMATOLOGY

Therapeutic Advances in Hematology Pub Date : 2025-10-06 eCollection Date: 2025-01-01 DOI:10.1177/20406207251359650

Wenhao Yang, Xiangtu Kong, Hui Yu, Xiaosu Feng, Haiwen Ni

{"title":"Comparative analysis of once-weekly versus twice-weekly carfilzomib in relapsed and refractory multiple myeloma: a meta-analysis.","authors":"Wenhao Yang, Xiangtu Kong, Hui Yu, Xiaosu Feng, Haiwen Ni","doi":"10.1177/20406207251359650","DOIUrl":null,"url":null,"abstract":"Background: While carfilzomib has shown effectiveness in treating relapsed or refractory multiple myeloma (RRMM), the best frequency of dosing is still debated. This meta-analysis aims to investigate the differences in safety and effectiveness between once-weekly and twice-weekly carfilzomib treatment schedules for patients with RRMM.Methods: A thorough search of five databases was performed. We calculated pooled relative risks (RRs), hazard ratios (HRs), and 95% confidence intervals (95% CIs), and conducted heterogeneity and sensitivity analyses using StateMP 18 software.Results: Five studies met the inclusion criteria. Analysis indicated that once-weekly carfilzomib significantly enhanced progression-free survival (HR: 0.80, 95% CI: 0.69-0.94, p = 0.007). However, no statistical difference was observed in the pooled RRs for overall response rate (RR: 1.13, 95% CI: 0.94-1.38, p = 0.198) and complete response or better (RR: 2.08, 95% CI: 0.65-6.65, p = 0.217). The once-weekly regimen was notably associated with a reduction in adverse events (RR: 0.98, 95% CI: 0.96-1.00, p = 0.047) relative to the twice-weekly regimen.Conclusion: The results propose once-weekly carfilzomib as a viable alternative treatment option for RRMM.","PeriodicalId":23048,"journal":{"name":"Therapeutic Advances in Hematology","volume":"16 ","pages":"20406207251359650"},"PeriodicalIF":3.1000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12501438/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Hematology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/20406207251359650","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: While carfilzomib has shown effectiveness in treating relapsed or refractory multiple myeloma (RRMM), the best frequency of dosing is still debated. This meta-analysis aims to investigate the differences in safety and effectiveness between once-weekly and twice-weekly carfilzomib treatment schedules for patients with RRMM.

Methods: A thorough search of five databases was performed. We calculated pooled relative risks (RRs), hazard ratios (HRs), and 95% confidence intervals (95% CIs), and conducted heterogeneity and sensitivity analyses using StateMP 18 software.

Results: Five studies met the inclusion criteria. Analysis indicated that once-weekly carfilzomib significantly enhanced progression-free survival (HR: 0.80, 95% CI: 0.69-0.94, p = 0.007). However, no statistical difference was observed in the pooled RRs for overall response rate (RR: 1.13, 95% CI: 0.94-1.38, p = 0.198) and complete response or better (RR: 2.08, 95% CI: 0.65-6.65, p = 0.217). The once-weekly regimen was notably associated with a reduction in adverse events (RR: 0.98, 95% CI: 0.96-1.00, p = 0.047) relative to the twice-weekly regimen.

Conclusion: The results propose once-weekly carfilzomib as a viable alternative treatment option for RRMM.

Abstract Image

查看原文本刊更多论文

卡非佐米治疗复发和难治性多发性骨髓瘤的比较分析：一项荟萃分析。

背景：虽然卡非佐米已显示出治疗复发或难治性多发性骨髓瘤（RRMM）的有效性，但最佳给药频率仍存在争议。本荟萃分析旨在调查每周一次和每周两次卡非佐米治疗方案对RRMM患者的安全性和有效性差异。方法：对5个数据库进行全面检索。我们计算了合并相对危险度（rr）、风险比（hr）和95%置信区间（95% ci），并使用StateMP 18软件进行了异质性和敏感性分析。结果：5项研究符合纳入标准。分析表明，每周一次的卡非佐米显著提高无进展生存期（HR: 0.80, 95% CI: 0.69-0.94, p = 0.007）。然而，总缓解率（RR: 1.13, 95% CI: 0.94-1.38, p = 0.198）和完全缓解或更好（RR: 2.08, 95% CI: 0.65-6.65, p = 0.217）的合并RRs无统计学差异。与每周两次的治疗方案相比，每周一次的治疗方案与不良事件的减少显著相关（RR: 0.98, 95% CI: 0.96-1.00, p = 0.047）。结论：研究结果表明，每周一次的卡非佐米是RRMM的可行替代治疗方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Hematology HEMATOLOGY-

CiteScore

4.30

自引率

0.00%

发文量

审稿时长

7 weeks

期刊介绍： Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.